Milestone Pharmaceuticals Inc (MIST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has a cash flow conversion efficiency ratio of -0.479x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.82 Million) by net assets ($20.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Milestone Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
Milestone Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Milestone Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Twinhead International Corp
TW:2364
|
0.089x |
|
Sino-Ocean Group Holding Limited
F:3SD
|
0.462x |
|
Genic Co. Ltd
KQ:123330
|
-0.124x |
|
Crosswood
PA:CROS
|
-0.020x |
|
Lotte Chemical Titan Tbk PT
JK:FPNI
|
0.100x |
|
Kukbo Design Co. Ltd
KQ:066620
|
0.056x |
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
0.070x |
|
MDxHealth SA ADR
NASDAQ:MDXH
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Milestone Pharmaceuticals Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Milestone Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.15 Million | $-28.85 Million | -2.194x | +20.73% |
| 2023-12-31 | $16.77 Million | $-46.42 Million | -2.768x | -250.03% |
| 2022-12-31 | $66.35 Million | $-52.47 Million | -0.791x | -168.02% |
| 2021-12-31 | $112.60 Million | $-33.22 Million | -0.295x | +16.76% |
| 2020-12-31 | $143.12 Million | $-50.73 Million | -0.354x | +20.36% |
| 2019-12-31 | $114.92 Million | $-51.15 Million | -0.445x | -216.77% |
| 2018-12-31 | $-55.21 Million | $-21.05 Million | 0.381x | +56.79% |
| 2017-12-31 | $-33.12 Million | $-8.05 Million | 0.243x | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more